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Background: Obstructive sleep apnea is a common sleep disorder in stroke patients. Obstructive sleep apnea is
associated with stroke severity and poor functional outcome. Continuous positive airway pressure seems to
improve functional recovery in stroke rehabilitation. To date, the effect of continuous positive airway pressure on
cognitive functioning in stroke patients is not well established. The current study will investigate the effectiveness
of continuous positive airway pressure on both cognitive and functional outcomes in stroke patients with
obstructive sleep apnea.
Methods/Design: A randomized controlled trial will be conducted on the neurorehabilitation unit of Heliomare, a
rehabilitation center in the Netherlands. Seventy stroke patients with obstructive sleep apnea will be randomly
allocated to an intervention or control group (n = 2×35). The intervention will consist of four weeks of continuous
positive airway pressure treatment. Patients allocated to the control group will receive four weeks of treatment as
usual. Outcomes will be assessed at baseline, immediately after the intervention and at two-month follow-up.
In a supplementary study, these 70 patients with obstructive sleep apnea will be compared to 70 stroke patients
without obstructive sleep apnea with respect to cognitive and functional status at rehabilitation admission.
Additionally, the societal participation of both groups will be assessed at six months and one year after inclusion.
Discussion: This study will provide novel information on the effects of obstructive sleep apnea and its treatment
with continuous positive airway pressure on rehabilitation outcomes after stroke.
Trial registration: Trial registration number: Dutch Trial Register NTR3412
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Functional statusBackground
Obstructive sleep apnea (OSA) is a sleep disorder charac-
terized by repetitive cessations of breathing during sleep
due to obstruction of the upper airway. The diagnosis of
OSA is based on the mean number of apneas and hypop-
neas per hour sleep, the apnea-hypopnea index (AHI).* Correspondence: j.aaronson@heliomare.nl
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reproduction in any medium, provided the orNighttime consequences of OSA are periodic oxygen
desaturations, increases in blood pressure and sleep frag-
mentation. OSA is associated with an increased risk for
cardiovascular diseases, such as hypertension, heart dis-
ease and stroke [1,2]. A recent meta-analysis [3] reported
a prevalence of sleep apnea between 38-72% in stroke pa-
tients compared to 3-28% in the general population [4].
The most frequently reported daytime consequences
of OSA are excessive daytime sleepiness and fatigue.
There is also growing evidence that OSA negatively af-
fects cognitive functioning and mood. Most studies findral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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tion, executive functioning, memory and motor coordin-
ation [5,6]. The etiology of the cognitive impairment in
OSA patients is still unclear, but neuroimaging studies
provide evidence that OSA is associated with structural
and functional changes in the brain, particularly in the
frontal cortex and hippocampus [7,8].
Continuous positive airway pressure (CPAP) is the
treatment of choice for OSA. CPAP improves breathing
during sleep, resulting in better blood oxygen saturation
and less sleep fragmentation [9]. Consequently, it is ex-
pected that CPAP treatment will improve daytime func-
tioning. However, evidence of the therapeutic effects of
CPAP on fatigue, cognitive functioning and mood is in-
consistent. A Cochrane review showed significant reduc-
tion of objective and subjective sleepiness, and depressive
symptoms, while in a recent meta-analysis of cognitive
functioning after CPAP we only found slight improvement
in the attention domain [10,11]. Notwithstanding this lim-
ited evidence for behavioral effects of CPAP treatment,
there are some indications that it results in structural
changes in the brain. One imaging study showed that
CPAP treatment was associated with increase of grey mat-
ter in the hippocampal and frontal structures [8].
OSA is a common sleep disorder in stroke and has
been reported to be associated with stroke severity, poor
functional outcome, recurrent stroke, and increased
mortality [2,12-14]. In a cross-sectional study in stroke
patients, OSA was found to be associated with delirium,
depressed mood and impaired activities of daily living,
but no relationship was seen between OSA and perform-
ance on a cognitive screening instrument (Mini Mental
State Examination; MMSE) [15]. The authors suggested
the use of more sensitive neuropsychological tests. We
conducted a pilot study examining the effect of OSA on
a set of neuropsychological tests in stroke patients [16].
In this small sample, OSA was found to be associated with
lower performance on tasks of attention, verbal memory
and visual scanning, and increased depressive symptoms.
To date, seven randomized controlled trials (RCTs) have
compared CPAP to treatment as usual (TAU) or sham
CPAP in stroke patients. Four of these studies found
improvement in CPAP compared to TAU in one or more
neurological function outcomes, sleepiness or mood
[15,17-19], while three RCTs found no benefit of CPAP
treatment in these areas compared to TAU or sham CPAP
[20-22]. The latter studies had low compliance and insuffi-
cient power due to small sample size, which may have
affected the results. The effect of CPAP on cognitive func-
tioning was evaluated in three studies. Two studies used
the MMSE [15,21] and one study [19] assessed the sus-
tained attention to response test (a measure of vigilance)
and the digit or spatial span backward test (a measure of
executive function). None of these cognitive measuresshowed improvement with CPAP. The effect on more ex-
tensive neuropsychological assessment including sensitive
measures of memory and attention has not yet been
investigated.
In summary, previous research suggests that OSA is
associated with poor functional outcome after stroke,
and that treatment with CPAP improves functional re-
covery during stroke rehabilitation. However, the effect
of OSA and CPAP treatment on cognitive functioning in
stroke patients is still unclear. The Treatment of OSA
and Rehabilitation Outcome in Stroke (TOROS) study is
designed to address these issues.
The TOROS project consists of a randomized con-
trolled trial (RCT), and a supplementary case–control
study. The primary objective of the RCT is to evaluate
whether CPAP treatment improves cognitive and func-
tional outcomes in stroke patients with OSA (AHI ≥ 15),
as assessed by a neuropsychological test battery and by
measures of neurological status and functional depend-
ence. The aim of the supplementary case–control study
is to explore the association between OSA and cognitive
and functional status in stroke patients. Our hypothesis
is that stroke patients with OSA have a poorer func-
tional status and greater cognitive impairment compared
to stroke patients without OSA. In both the RCT and
the case–control study the secondary objectives are: 1)
to evaluate the effects of OSA (and its treatment) on
sleep quality, fatigue and mood; and 2) to evaluate the
long-term effects of OSA on societal participation.
Methods
Design
In the RCT, 70 OSA patients will be randomized to re-
ceive four weeks of CPAP treatment or four weeks of
TAU. Patients randomized to TAU will start with CPAP
treatment after the four-week intervention period. Neuro-
psychological assessment and examination of functional
status, the primary outcome measures, are conducted at
baseline and repeated after the four-week intervention
period and at two-month follow-up. The secondary mea-
sures sleep quality, fatigue, and mood are assessed at the
same time points as the primary outcome measures. To
ascertain whether OSA improves with CPAP treatment,
direct measurements of OSA, including AHI and level of
oxygen desaturation during sleep, are made at baseline, at
the end of the intervention period, and at two-month
follow-up. To assess treatment compliance, the CPAP
device registers CPAP usage per night, the air pressure
and the residual AHI. At four weeks, and three, six and
twelve months after enrollment the rehabilitation phys-
ician checks the compliance.
To test the hypothesis of the case–control study that
OSA is associated with poor functional status and greater
cognitive impairment, 70 stroke patients diagnosed with
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the primary and secondary outcomes at admission to the
rehabilitation unit (baseline).
In a subgroup of the stroke patients without OSA
(N = 35) the assessment of primary and secondary out-
come measures will be repeated after four weeks and
three months. The outcomes will be compared to the re-
covery of OSA patients.
All patients included in the TOROS study are asked to
fill out a questionnaire on participation in work, leisure
and social activities at six months and one year after in-
clusion. The study design is illustrated in Figure 1.
The Medical Ethical Review Board of the Academic
Medical Centre, Amsterdam, approved the study. The
inclusion period started in October 2011. The study is
registered at the Dutch trial register (http://www.trial-
register.nl) and identified as NTR3412.
Patient sample and procedures
This study is conducted in Heliomare rehabilitation center
in the Netherlands. Annually, approximately 150 stroke pa-
tients are admitted to Heliomare. Neurologists or rehabili-
tation physicians of hospitals in the surrounding area refer
patients. Patients with vascular dementia or comorbidFigure 1 Flowchart of the TOROS study. OSA: obstructive sleep apnea; Cneurodegenerative diseases (e.g., Alzheimer’s or Parkinson’s
disease) are excluded from rehabilitation in Heliomare and
are referred to the rehabilitation unit of a nursing home.
The majority of the admitted patients are in the post-acute
phase, i.e., on average, two to three weeks post-stroke. The
average length of stay in Heliomare is nine weeks (standard
deviation of four weeks). An earlier study showed that the
prevalence of OSA in stroke patients admitted to Helio-
mare is around 50% [23]. At admission to the rehabilitation
unit, stroke severity and functional dependence scales are
used to determine the patient’s functional status. In the
first week of hospitalization, patients are interviewed with
a questionnaire to determine the presence of common
symptoms of OSA. Subsequently, their oxygen desatur-
ation index (ODI), defined as the mean number of desa-
turations of ≥3% from baseline per hour, is assessed with
nocturnal pulse oximetry. Patients with an ODI of five or
higher are further tested for OSA by polygraphy. Patients
with an AHI of 15 or higher on polygraphy are diagnosed
with OSA and patients with a normal ODI (<5) [23,24] or
AHI below 15 are defined as non-OSA patients. Within
four weeks of admission, a neuropsychological assessment
is administered to determine the level of cognitive func-
tioning. Stroke patients meeting the following inclusionPAP: continuous positive airway pressure; TAU: treatment as usual.
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admission to Heliomare: [1] stroke confirmed by a neur-
ologist, [2] age between 18 and 85 years, [3] admission to
Heliomare between 1 and 16 weeks post-stroke, and [4]
able to participate in the OSA screening and neuropsycho-
logical assessment. Exclusion criteria are: [1] severe un-
stable medical conditions, respiratory failure or history of
severe congestive heart failure, [2] traumatic brain injury,
[3] severe aphasia, confusion or psychiatric comorbidity,
[4] central sleep apnea or previously diagnosed OSA. Pa-
tients with severe OSA (AHI >60 and oxygen desaturations
below 70%), which could endanger the patient’s health if
treatment is not immediately started, are excluded from
the RCT part of the study. Before inclusion, patients give
written informed consent.Randomization and blinding
Participants with OSA will be randomized immediately
after the baseline assessments. The minimization tech-
nique [25] will be used to minimize imbalance between
the treatment arms for age, severity of OSA, stroke sub-
type (ischemic or hemorrhage) and severity of cognitive
impairment. Assessors of cognitive and functional out-
come measures will be blinded to treatment allocation.Table 1 Neuropsychological tests by cognitive domain
Cognitive domain Neuropsychological test
Vigilance Psychomotor vigilance task
Attention D-Kefs trail making test (TMT)
*Color trails test
d2 Test of attention
Memory Rey’s auditory verbal learning test
*Location learning test
Working Memory WAIS-III letter-number sequencing
*WMS-IV symbol span
Executive functioning D-Kefs TMT letter-number switching
Tower of London
Language GIT-II category fluency
**Token test
Visuoperception D-Kefs TMT visual scanning
Bells test
Psychomotor ability D-Kefs TMT motor speed
Finger tapping
Intelligence WAIS-III matrix reasoning
*non-verbal alternative; **only administered in patients with aphasia.Intervention
CPAP treatment is set up and monitored by a specialized
‘Respicare’ team. This team exists of two rehabilitation
physicians, two nurse practitioners and four nurses work-
ing on the neurorehabilitation unit specialized in sleep
and breathing disorders. Before treatment is initiated, a
CPAP mask, connecting hose and CPAP device are set up
for each patient. Different masks are used, from small
nasal pillows to a full-face mask, depending on the pa-
tient’s preference. Personalized instructions are given by
one of the Respicare team members and a written manual
for the CPAP device is provided. If possible, the partner or
a close relative is also provided with instructions on the
use of the CPAP device. Patients are asked to wear the
mask for a short period during the day to become accus-
tomed to using the CPAP device. Within the first week,
the CPAP treatment is evaluated together with the patient
and CPAP titration is performed using pulse oximetry.
The pressure is adjusted until the ODI is reduced to nor-
mal (ODI <5). If titration by nocturnal oximetry fails to
adequately reduce the ODI, CPAP is titrated by polygra-
phy to reduce the AHI to <5 or to the highest pressure
tolerated. The CPAP device is provided with a memory
card to evaluate the effectiveness of CPAP therapy over
time and to monitor CPAP compliance. The Respicare
team has contact with the patients regularly during the
intervention period to help troubleshoot problems and en-
courage compliance. Patients who are discharged duringthe four-week intervention period are followed-up by
telephone.Primary outcomes
The primary outcome measures of this study are cognition
and functional status. The following nine cognition do-
mains are assessed: vigilance, attention, memory, working
memory, executive functioning, language, visuoperception,
psychomotor ability and intelligence. The neuropsycho-
logical test battery of standardized neuropsychological tests
[26] is assessed by a trained psychological assistant. For a
number of cognitive domains, non-verbal alternative tests
are included for patients with aphasia. A language compre-
hension test is also included for aphasic patients. The ob-
tained test scores are transformed into demographically
corrected z-scores. In case of multiple tests within one do-
main, the average z-score for the domain is calculated. In
Table 1 all tests are summarized by cognitive domain.
Functional status is assessed by measures of neuro-
logical status and functional dependence. The rehabilita-
tion physician administers two scales of neurological
status, the Canadian Neurological Scale [27] and the
National Institutes of Health Stroke Scale [28]. The ob-
tained scores are transformed into z-scores and averaged
into one score for neurological status. The nurse practi-
tioner scores the level of functional dependence on the
Utrecht Scale for Evaluation of Rehabilitation [29]. This
scale can be converted to the Barthel Index [30].
Aaronson et al. BMC Neurology 2014, 14:36 Page 5 of 7
http://www.biomedcentral.com/1471-2377/14/36Secondary outcomes
Secondary outcome measures of the TOROS study are
sleepiness (Stanford Sleepiness Scale), fatigue (Checklist In-
dividual Strength), mood (Hospital Anxiety and Depression
Scale), and subjective sleep quality (Sleep Quality Scale)
[31-34]. A trained psychological assistant administers these
measures after the neuropsychological assessment. The
Utrecht Scale for Evaluation of Rehabilitation – Participa-
tion [35] is used to evaluate work, leisure and social activ-
ities at six months and one year after the inclusion. The
patients complete this questionnaire at home.
Objective measurements of sleep are made using stan-
dardized pulse oximetry (WristOx®; Nonin Medical,
Plymouth, USA) and ambulatory overnight cardiorespi-
ratory polygraphy (Embletta®; Embla, Ottowa, Canada).
The ODI (mean number of oxygen desaturations of ≥3%
per hour) is calculated from the pulse oximetry data
using automated analysis. Trained staff manually scores
the polygraph recordings. Apnea is defined as a reduc-
tion of airflow of ≥90% for at least 10 seconds and
hypopnea is defined as a reduction of airflow of ≥50%
for at least 10 seconds followed by an oxygen desatur-
ation of ≥3%. The AHI is defined as the mean number
of apneas and hypopneas per hour in bed. The change
of AHI measured by polygraphy and treatment compli-
ance are used as moderating variables in the RCT.
A self-report questionnaire is administered to identify
OSA symptoms (e.g., snoring, daytime sleepiness, morn-
ing headaches). Socio-demographic and clinical charac-
teristics such as age, sex, education, body mass index
(BMI), medication use and life style variables (e.g., smok-
ing) are obtained from medical records.
Sample size
We conducted two separate power analyses for the RCT;
one for the functional outcome and one for the cognitive
outcome. The power calculation for the functional out-
come is based on two previous studies [18,19]. These
studies found large effects of CPAP treatment on func-
tional outcome measures in stroke patients. To detect at
least one standard deviation (large effect) on functional
outcome with 90% power and an alpha of 0.05 (one-
tailed), a minimum of 34 patients (17 per arm) is required.
No reliable information on the expected effect of CPAP
treatment on cognitive measures is available. Therefore,
an effect size of 0.75 standard deviation was used to esti-
mate the necessary sample size. Taken the same alpha
level and 80% power, a minimum of 56 patients (28 per
arm) needs to be included in the RCT. The compliance in
this study is expected to be relatively high (around 67%)
due to the relatively short duration of the experimental
treatment phase and the assistance of a specially trained
staff. Taking the compliance rate into account, a total of
70 patients will be the target sample size for the RCT.For the supplementary case–control study, we set the
sample size at 70 OSA patients and 70 patients without
OSA, which allows detection of a medium size effect (0.5
standard deviation) with 90% power, and p-value set at 0.5.
Statistical analyses
All statistical analyses will be performed with SPSS 19
(IBM; Armonck, USA) or later versions of this package.
Depending on the level of measurement, parametric sta-
tistics (Student’s t-test and analysis of (co)variance) or
non-parametric statistics (χ2 and Fisher’s exact test) will
be used. Statistical significance will be set at a p-value of
0.05 or less. Socio-demographic and clinical characteris-
tics at baseline will be presented using descriptive statis-
tics. If group differences are observed at baseline on one
or more background variables, those variables will be in-
cluded as covariates in all further analyses.
For the RCT, the therapy effects on the primary and
secondary outcome measures will be examined using a
two factor (group × time) multivariate analysis of vari-
ance (MANOVA). Effect sizes will be calculated for all
analyses using standard statistical procedures. To control
for the multiple comparisons of cognition and functional
status, two separate MANOVA’s will be performed. Given
that we have two primary outcomes defined for the study
(i.e., cognitive and functional outcomes), we will subse-
quently follow Hochberg’s step-up procedure [36] to con-
trol the false discovery rate.
Data will be analyzed according to the intention-to-
treat principle. Additionally, a per-protocol analysis will
be performed. Depending on the variability of compli-
ance, a secondary analysis of good versus poor compli-
ance will be conducted. In an exploratory analysis, we
will investigate whether the effectiveness of CPAP ther-
apy varies as a function of clinical diagnosis, level of cog-
nitive functioning, and demographic background.
For the supplementary case–control part of the study,
OSA patients will be compared with the control group
of non-OSA patients on primary and secondary outcome
measures using a MANOVA. As with the RCT, a separ-
ate analysis will be performed for cognition and func-
tional status, and the Hochberg’s step-up procedure will
be followed. For the follow-up of the USER-P question-
naire, within group changes will be assessed using paired
t-tests and between group comparison will be made with
two sample t-test.
Discussion
Sleep apnea is highly prevalent in stroke patients. The
TOROS study is designed primarily to evaluate the effect
of CPAP treatment on improvement of rehabilitation out-
come in stroke patients. In the RCT part of the study, con-
ducted in stroke patients with OSA, CPAP treatment is
compared to TAU on both functional and cognitive
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functional status [17-19], but the effect of CPAP on cogni-
tive functioning in stroke patients with OSA remains un-
clear. CPAP treatment of OSA patients who did not suffer
stroke has only a limited effect on cognitive functioning
[11]. However, stroke patients with OSA have much
more to gain with respect to cognitive functioning than
these ‘regular’ OSA patients. Thus, the cognitive effects
of CPAP treatment may be much larger in stroke pa-
tients with OSA.
Treatment compliance is a major practical problem
with CPAP. A number of earlier studies investigating the
effects of CPAP treatment suffered from low compliance
[20-22]. To ensure treatment compliance within this pro-
ject, a specialized Respicare team will carefully monitor
patients receiving CPAP treatment in order to quickly
detect and resolve problems, and motivate patients to
continue use of the treatment. We expect that this will en-
hance treatment compliance.
The supplementary case–control study will improve
our understanding of the association between OSA and
cognitive impairments in the rehabilitation of stroke pa-
tients. Previous studies provide provisional evidence that
OSA in stroke patients is associated with poor functional
outcome [13], but the association between OSA and
cognitive functioning in stroke patients is far from clear.
Studies conducted in regular sleep clinics found that
OSA negatively affected several cognitive domains [5,6].
Therefore, it is expected that OSA in stroke patients is
associated with poor cognitive outcome.
There are several limitations to the TOROS study that
should be noted. Firstly, we perform polygraphy rather than
polysomnography to diagnose OSA. Our experience is that
polygraphy is often better tolerated by stroke patients, but
polygraphy has the disadvantage that it may give an under-
estimation of the AHI in case of low sleep efficiency. Other
limitations of the study are the relatively small sample size
and short CPAP intervention period. These are practical
limitations that cannot be overcome given both financial
and time constraints in carrying out this research.
Conclusions
To date, there are no guidelines for the screening and
treatment of OSA in stroke rehabilitation. We believe
that the TOROS study will add to the understanding of
the clinical implications of OSA in stroke rehabilitation,
and the effects of CPAP treatment on the rehabilitation
outcome. This, in turn, will provide rehabilitation physi-
cians with evidence to help formulate future guidelines
for OSA in stroke patients.
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